About Marker Therapeutics, Inc.
https://www.markertherapeutics.comMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States.
CEO
Juan F. Vera
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-01-27 | Reverse | 1:10 |
| 2016-09-16 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
NEA MANAGEMENT COMPANY, LLC
Shares:1.63M
Value:$2.96M
BLUE OWL CAPITAL HOLDINGS LP
Shares:554.25K
Value:$1.01M
ACT CAPITAL MANAGEMENT, LLC
Shares:354.4K
Value:$645.01K
Summary
Showing Top 3 of 37
About Marker Therapeutics, Inc.
https://www.markertherapeutics.comMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.23M ▲ | $3.37M ▲ | $-2M ▲ | -162.11% ▲ | $-0.12 ▲ | $-2M ▲ |
| Q2-2025 | $861.18K ▲ | $945.16K ▼ | $-4.02M ▲ | -466.28% ▲ | $-0.29 ▲ | $-4.26M ▼ |
| Q1-2025 | $349.1K ▼ | $1.82M ▲ | $-4.45M ▼ | -1.27K% ▼ | $-0.4 ▲ | $0 ▲ |
| Q4-2024 | $2.25M ▲ | $1.03M ▲ | $-3.84M ▼ | -170.43% ▼ | $-0.42 ▼ | $-3.86M ▼ |
| Q3-2024 | $1.93M | $854.68K | $-2.31M | -119.83% | $-0.26 | $-2.4M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $17.59M ▲ | $21.73M ▲ | $3.35M ▼ | $18.39M ▲ |
| Q2-2025 | $10.46M ▼ | $14.77M ▼ | $4.28M ▲ | $10.49M ▼ |
| Q1-2025 | $13.69M ▼ | $16.99M ▼ | $2.5M ▼ | $14.49M ▼ |
| Q4-2024 | $19.19M ▲ | $22.02M ▲ | $3.46M ▲ | $18.56M ▲ |
| Q3-2024 | $9M | $10.91M | $3.46M | $7.45M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-2M ▲ | $-2.74M ▼ | $0 | $9.86M ▲ | $7.13M ▲ | $-2.74M ▼ |
| Q2-2025 | $-4.02M ▲ | $-1.88M ▲ | $0 | $100 ▼ | $-1.88M ▲ | $-1.88M ▲ |
| Q1-2025 | $-4.45M ▼ | $-5.5M ▼ | $0 | $505 ▼ | $-5.5M ▼ | $-5.5M ▼ |
| Q4-2024 | $-3.84M ▼ | $-4.7M ▼ | $0 | $14.9M ▲ | $10.19M ▲ | $-4.7M ▼ |
| Q3-2024 | $-2.31M | $1.2M | $0 | $1.7K | $1.2M | $1.2M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Grant | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Juan F. Vera
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-01-27 | Reverse | 1:10 |
| 2016-09-16 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
NEA MANAGEMENT COMPANY, LLC
Shares:1.63M
Value:$2.96M
BLUE OWL CAPITAL HOLDINGS LP
Shares:554.25K
Value:$1.01M
ACT CAPITAL MANAGEMENT, LLC
Shares:354.4K
Value:$645.01K
Summary
Showing Top 3 of 37